|Bid||235.00 x 243000|
|Ask||232.00 x 260500|
|Day's Range||231.60 - 235.05|
|52 Week Range||226.10 - 273.00|
|PE Ratio (TTM)||20.70|
|Forward Dividend & Yield||8.22 (3.22%)|
|1y Target Est||N/A|
Merck surged to a three-month high Tuesday on strong results for its immuno-oncology and chemotherapy regimen in lung cancer.
Roche's (RHHBY) multiple sclerosis drug Ocrevus gets approval in Europe thereby boosting its neuroscience portfolio. The drug is already approved in the United States.
The question for patients with early-stage HER2+ breast cancer is if it’s worth taking a treatment (Nerlynx) that lowers the risk of distant recurrence by less than 2% at 5 years, and which has not yet been studied over the long term.
It’s safer to invest in, cheap and offers a huge potential in continued earnings recovery. As the big investment banks start to look ahead to 2018, UBS has already picked one of its favorites and the needle ...
Drugmakers plunged off a patent cliff earlier this decade, losing billions in sales as lucrative branded drugs lost exclusivity. An expensive lobbying effort aimed at preventing a repeat is paying off....
Roche Holding AG led European stocks lower after the Swiss pharmaceutical company unveiled data on the Aphinity breast-cancer study that disappointed analysts.